General Information of Drug (ID: DMQD1GN)

Drug Name
JNJ-32729463
Synonyms
Acorafloxacin HCl; Avarofloxacin hydrochloride; Acorafloxacin hydrochloride; UNII-1NWW5SKQ0N; JNJ-32729463-AAC; 1NWW5SKQ0N; Acorafloxacin hydrochloride [USAN]; 1001162-01-1 (HCl); Acorafloxacin hydrochloride (USAN); Avarofloxacin HCl; 1001162-01-1; (E)-7-(3-(2-amino-1-fluoroethylidene)piperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride; JNJ-Q2 hydrochloride; SCHEMBL2190495; CHEMBL2364603; DTXSID70142966; JNJ-32729463AAC; Jnj-32729463; 7-((3E)-3-(2-Amino-1-fluoroethylidene)-1-piperidinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid hydrochloride; D10544; Q27252661
Indication
Disease Entry ICD 11 Status REF
Community-acquired pneumonia CA40.Z Phase 2 [1]
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski):
0
Molecular Weight 455.9
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 5
Hydrogen Bond Donor Count 3
Hydrogen Bond Acceptor Count 9
Chemical Identifiers
Formula
C21H24ClF2N3O4
IUPAC Name
7-[(3E)-3-(2-amino-1-fluoroethylidene)piperidin-1-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid;hydrochloride
Canonical SMILES
COC1=C2C(=CC(=C1N3CCC/C(=C(/CN)\\F)/C3)F)C(=O)C(=CN2C4CC4)C(=O)O.Cl
InChI
InChI=1S/C21H23F2N3O4.ClH/c1-30-20-17-13(19(27)14(21(28)29)10-26(17)12-4-5-12)7-15(22)18(20)25-6-2-3-11(9-25)16(23)8-24;/h7,10,12H,2-6,8-9,24H2,1H3,(H,28,29);1H/b16-11+;
InChIKey
RDXCNSOGHLLWDV-YFMOEUEHSA-N
Cross-matching ID
PubChem CID
67311433
CAS Number
1001162-01-1
TTD ID
D39VXL

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU ; GYRB_STAAU Inhibitor [2]
Bacterial DNA topoisomerase 4A (Bact parC) TTFK8YB PARC_ECOLI Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01198626) Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia. U.S. National Institutes of Health.
2 Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2. Antimicrob Agents Chemother. 2011 Dec;55(12):5512-21.